$Daxor (DXR.US)$ NEWS New Studies Prove the Clinical Benefit...
NEWS
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at the American College of Cardiology Scientific Sessions and published in the American Heart Journal showcase the value of BVA in improving outcomes and managing heart failure.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
3021Followers
109Following
31KVisitors
Follow